Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Pleyer, Lisa, Döhner, Hartmut, Dombret, Hervé, Seymour, John F., Schuh, Andre C., Beach, CL, Swern, Arlene S., Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva M., Lang, Alois, Geissler, Klaus, Voskova, Daniela, Sperr, Wolfgang R., Hojas, Sabine, Rogulj, Inga M., Andel, Johannes, Greil, Richard
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343949/
https://ncbi.nlm.nih.gov/pubmed/28212292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18020415
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki